RECOVER (NOLVA) is a popular and powerfully effective Selective Estrogen Receptor Modulator (SERM) that is often referred to as an anti-estrogen. However, while being an antagonist it is also an agonist as it will actually act as estrogen in certain parts of the body while acting as an anti-estrogen in other areas. As one of the oldest SERM’s on the market that is still regularly used medicinally, while RECOVER (NOLVA) is also used by anabolic steroid users it is not an anabolic steroid. This is an important note as some are often confused by its use in steroid cycles.

As an anti-estrogen, RECOVER (NOLVA) functions by binding to the estrogen receptors in the place of estrogen. This binding prevents the estrogen hormone from performing its action in certain parts of the body, which is precisely why it’s beneficial to breast cancer patients. Many forms of breast cancer actually feed off estrogen when it attaches to the receptors in the chest. By preventing the attachment in such receptors, this also protects anabolic steroid users from gynecomastia, which can be caused by anabolic steroids that aromatize such as Testosterone, Dianabol, and Nandrolone and Boldenone to a degree.

Dosage

Concentration: 40mg/mL

Volume: 30mL

We suggest a dosage of 20-40mg (0.5-1ml) everyday for 4 weeks. Each bottle is 30ml in volume and will last for around 30 days.

Ingredients

RECOVER (NOLVA): (Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine, Food-grade USP glycol, food-grade ethyl alcohol and essential oils.

Medical References

1. Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ (Jul 2014). "Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update". Journal of Clinical Oncology. 32 (21): 2255–69.
2. Dueñas-Díez, edited by Antonio Cano Sanchez, Joaquim Calaf i Alsina, José-Luis (2006). Selective Estrogen Receptor Modulators a New Brand of Multitarget Drugs. Berlin, Heidelberg: Springer-Verlag Berlin Heidelberg. p. 52.
   
3. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S (Sep 2007). "Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts". Cell. 130 (5): 811–23.
   

Storage

Cool and dark space like a cupboard or pantry.

No statements made on this page have been evaluated by the Bundesministerium für Gesundheit (BMG) or the Therapeutic Goods Administration (TGA). These products are not intended to treat, cure or prevent any disease or illness. All products are strictly for research purposes only. Please refer to the TERMS OF USE for more information.